These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Asati V; Mahapatra DK; Bharti SK Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863 [TBL] [Abstract][Full Text] [Related]
5. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Gollob JA; Wilhelm S; Carter C; Kelley SL Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795 [TBL] [Abstract][Full Text] [Related]
6. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Faivre S; Djelloul S; Raymond E Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796 [TBL] [Abstract][Full Text] [Related]
8. Novel anti-cancer agents in development: exciting prospects and new challenges. Seymour L Cancer Treat Rev; 1999 Oct; 25(5):301-12. PubMed ID: 10544074 [TBL] [Abstract][Full Text] [Related]
9. A historical overview of protein kinases and their targeted small molecule inhibitors. Roskoski R Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888 [TBL] [Abstract][Full Text] [Related]
11. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer]. Leirdal M; Sioud M Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574 [TBL] [Abstract][Full Text] [Related]
12. Overview on Anticancer Drug Design and Development. Olgen S Curr Med Chem; 2018; 25(15):1704-1719. PubMed ID: 29189124 [TBL] [Abstract][Full Text] [Related]
13. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173 [TBL] [Abstract][Full Text] [Related]
14. [Progress in the study of antitumor drug targeting on the Ras signaling pathway]. Zhu YJ; Jiang FC Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814 [TBL] [Abstract][Full Text] [Related]
15. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761 [TBL] [Abstract][Full Text] [Related]
16. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498 [TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. Cepero V; Sierra JR; Giordano S Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985 [TBL] [Abstract][Full Text] [Related]
18. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. Asati V; Mahapatra DK; Bharti SK Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185 [TBL] [Abstract][Full Text] [Related]